Tejas Patil

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9283023/publications.pdf

Version: 2024-02-01

57 papers	1,469 citations	687363 13 h-index	345221 36 g-index
59 all docs	59 docs citations	59 times ranked	1806 citing authors

#	Article	IF	Citations
1	Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib. Clinical Lung Cancer, 2022, 23, e5-e8.	2.6	11
2	Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. Journal of Thoracic Oncology, 2022, 17, 116-129.	1.1	50
3	In Response to: â€œComparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?â€. Journal of Thoracic Oncology, 2022, 17, e12-e14.	1.1	0
4	Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?. Clinical Cancer Research, 2022, , OF1-OF2.	7.0	0
5	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. Oncologist, 2022, , .	3.7	18
6	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusionâ€“Positive NSCLC. JTO Clinical and Research Reports, 2022, 3, 100332.	1.1	15
7	Association of anticoagulant use with clinical outcomes from crizotinib in ALK <scp> â€ </scp> and ROS1 â€rearranged advanced nonâ€small cell lung cancers: A retrospective analysis of <scp>PROFILE</scp> 1001. Cancer Medicine, 2022, , .	2.8	2
8	2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist, 2021, 26, e454-e472.	3.7	17
9	CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusionsâ€”A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).. Journal of Clinical Oncology, 2021, 39, TPS449-TPS449.	1.6	2
10	MO01.33 CRESTONE â€“ Clinical Study of REsponse to Seribantumab in Tumors with NEuregulin-1 (NRG1) Fusions â€“ A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210). Journal of Thoracic Oncology, 2021, 16, S29-S30.	1.1	2
11	P76.14 Time to First Progression in Patients with NSCLC with Brain Metastases Receiving 3rd Generation TKI alone vs TKI + Brain Radiation. Journal of Thoracic Oncology, 2021, 16, S591-S592.	1.1	0
12	FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study. Journal of Thoracic Oncology, 2021, 16, S229-S230.	1.1	2
13	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 41.	5.4	22
14	Duration of pemetrexed maintenance therapy with or without pembrolizumab is associated with risk of renal toxicity in patients with metastatic nonsquamous NSCLC.. Journal of Clinical Oncology, 2021, 39, e21205-e21205.	1.6	0
15	Effect of continuing osimertinib with chemotherapy in the post-progression setting on progression-free survival among patients with metastatic epidermal growth factor receptor (EGFR) positive non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 9124-9124.	1.6	1
16	Acquired Resistance to KRAS^{G12C} Inhibition in Cancer. New England Journal of Medicine, 2021, 384, 2382-2393.	27.0	482
17	Abstract 1375: Activity of pemetrexed in patients with driver oncogene positive non-small cell lung cancer and squamous histology. , 2021, , .		0
18	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clinical and Research Reports, 2021, 2, 100187.	1.1	11

#	Article	IF	Citations
19	Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer. , 2021, , .		8
20	Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. Npj Precision Oncology, 2021, 5, 91.	5.4	5
21	P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results. Journal of Thoracic Oncology, 2021, 16, S1039-S1040.	1.1	6
22	Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology. Frontiers in Oncology, 2021, 11, 788245.	2.8	3
23	Epidemiology and treatment trends for primary tracheal squamous cell carcinoma. Laryngoscope, 2020, 130, 405-412.	2.0	5
24	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e191-e204.	2.6	26
25	Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 510.	2.8	3
26	Duration of Targeted Therapy in Patients With Advanced Nonâ€“small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clinical Lung Cancer, 2020, 21, 545-552.e1.	2.6	11
27	Untapped potential: recognising CNS opportunities in early oncology drug development. Lancet Oncology, The, 2019, 20, 1620-1622.	10.7	0
28	Extending the Duration of Efficacy of Targeted Therapies with Radiation to Oligoprogressive Disease (OPD) in Oncogene-Driven Metastatic Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2019, 105, S149.	0.8	0
29	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. Journal of Thoracic Oncology, 2019, 14, 596-605.	1.1	56
30	P2.03-06 Detection of ctDNA and Correlation with Tumor Mutation Testing in Early Stage NSCLC. Journal of Thoracic Oncology, 2019, 14, S684.	1.1	0
31	P1.14-27 Duration of Targeted Therapy in Advanced NSCLC (aNSCLC) with Drivers Identified by Circulating Tumor DNA (ctDNA) Analysis. Journal of Thoracic Oncology, 2019, 14, S564.	1.1	0
32	P1.01-87 Osimertinib Acquired Resistance Mechanisms and Post-Progression Outcomes in Stage IV EGFR Positive Non-Small Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S394.	1.1	0
33	Predictive value of oncogenic driver subtype, programmed deathâ€1 ligand (PDâ€L1) score, and smoking status on the efficacy of PDâ€1/PDâ€L1 inhibitors in patients with oncogeneâ€driven nonâ€“small cell lung cancer. Cancer, 2019, 125, 1038-1049.	4.1	66
34	NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.. Journal of Clinical Oncology, 2019, 37, 9081-9081.	1.6	11
35	Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs of Today, 2019, 55, 641.	1.1	16
36	Tucatinib. HER2 (ErbB2) inhibitor, Treatment of breast and colorectal cancer. Drugs of the Future, 2019, 44, 11.	0.1	0

#	Article	IF	Citations
37	Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study.. Journal of Clinical Oncology, 2019, 37, 9090-9090.	1.6	0
38	NRG1 Fusion-Positive Lung Cancers: Clinicopathologic Profile and Treatment Outcomes from a Global Multicenter Registry. , 2019, , .		0
39	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2018, 13, 134-138.	1.1	21
40	MA02.01 ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events. Journal of Thoracic Oncology, 2018, 13, S357-S358.	1.1	0
41	P1.01-78 The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib. Journal of Thoracic Oncology, 2018, 13, S492-S493.	1.1	0
42	Miliary Metastases in Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 1945-1945.	27.0	8
43	Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. Lung Cancer, 2018, 126, 112-118.	2.0	14
44	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Nonâ€“Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. Journal of Thoracic Oncology, 2018, 13, 1717-1726.	1.1	119
45	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Nonâ€“Small-cell Lung Cancer With Different Prognostic Significance. Clinical Lung Cancer, 2018, 19, 531-543.	2.6	3
46	New therapies for anaplastic thyroid cancer. Drugs of Today, 2018, 54, 695.	1.1	6
47	Management of Brain Metastases in Tyrosine Kinase Inhibitorâ€“NaÃ¯ve Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal of Clinical Oncology, 2017, 35, 1070-1077.	1.6	372
48	Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer, 2017, 109, 28-35.	2.0	10
49	P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results. Journal of Thoracic Oncology, 2017, 12, S696.	1.1	1
50	The role of positron emission tomography fused with computed tomography (PET/CT) versus CT alone in detecting oligoprogressive disease (OPD) in oncogene-addicted non-small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitor (TKI) therapy.. Journal of Clinical Oncology, 2017, 35, e20683-e20683.	1.6	0
51	Smad4 expression and chemosensitivity in non-small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, e20550-e20550.	1.6	1
52	The answer is skin deep: A case of intravascular large B cell lymphoma presenting as progressive paresis and bilateral abducens nerve palsy. Case Reports in Clinical Pathology, 2016, 3, .	0.0	0
53	G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy. European Journal of Cancer, 2016, 69, S143-S144.	2.8	1
54	PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, S313.	1.1	0

#	Article	IF	Citations
55	Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer, 2016, 96, 27-32.	2.0	20
56	Deferring Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: A Multi-Institutional Analysis. International Journal of Radiation Oncology Biology Physics, 2016, 96, S57-S58.	0.8	1
57	On the ontological assumptions of the medical model of psychiatry: philosophical considerations and pragmatic tasks. Philosophy, Ethics, and Humanities in Medicine, 2010, 5, 3.	1.5	38